Europe Approves Empagliflozin for Chronic Kidney Disease
The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.
Medscape Medical News
source https://www.medscape.com/viewarticle/994859?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/994859?src=rss
Comments
Post a Comment